Clinical Trial Update: Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer (DORA) [Phase 2]

View source ↗

Summary

Phase II multicenter trial evaluating durvalumab plus olaparib for platinum-treated advanced triple-negative breast cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Durvalumab (durvalumab)
• Olaparib (Olaparib)

Snippet

Sponsor: Duke University | Conditions: Triple Negative Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2022-09-13